AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Patients switched from tamoxifen to exemestane more likely to stay cancer-free.
2004 APR 1 - (NewsRx.com & NewsRx.net) -- In a large clinical trial, postmenopausal breast cancer patients who switched from tamoxifen to exemestane tablets (Pfizer brand name: Aromasin) had a significantly reduced chance of recurrence and increased disease-free survival compared to patients who remained on tamoxifen.
The Intergroup Exemestane Study (IES) involved over 4,700 postmenopausal women from 37 countries who had breast cancer and were followed for an average of 31 months. According to a current treatment paradigm, postmenopausal women with estrogen-receptor positive breast cancer receive tamoxifen for 5 years after surgery to prevent recurrence.
According to data published in the March 10, 2004, New England Journal of Medicine, the IES demonstrated that patients who switched to Aromasin after 2 or 3 years of taking tamoxifen were more likely to remain cancer-free than those who continued on tamoxifen. Patients receiving Aromasin experienced a 32% reduction in the risk of recurrence of the disease at 3 years, as compared to those continuing on tamoxifen. This reduction includes fewer local and distant tumors as well as new cancer in the other breast.
"Results from this study are important since many patients taking tamoxifen alone relapse within 5 years of diagnosis," said Charles Coombes, MD, lead investigator and head of the Department of Cancer Medicine, Imperial College School of Medicine in England. "This is the first large multi-center trial to ...
- Two drinks a day increases risk of breast cancer, study shows.
- Magazine article from: Women's Health Weekly March 4, 2004 700+ words
...MD, founder of The Breast Cancer Care & Research...or hopeful time for breast cancer research and treatment...for their particular breast cancer." This article was prepared by Women's Health Weekly editors from staff...
- Irsogladine side-steps angiogenic function to stop breast cancer metastasis.
- Magazine article from: Women's Health Weekly March 25, 2004 700+ words
...agent, irsogladine. Breast Cancer Res Treat, 2004...publisher of the journal Breast Cancer Research and Treatment...Gastroenterology, Oncology, and Breast Cancer. This article was prepared by Women's Health Weekly editors from staff...
- Change on enzyme gene may associate with invasive disease.(breast cancer...
- Magazine article from: Women's Health Weekly January 9, 2003 700+ words
...than women without breast cancer carried a polymorphism...MMP-3 * Women whose breast cancer had spread were more...metastasis in women with breast cancer This article was prepared by Women's Health Weekly editors from staff...
- Protein tyrosine phosphatase gamma is a tumor suppressor gene in breast cancer.
- Magazine article from: Women's Health Weekly April 1, 2004 700+ words
...independent growth of breast cancer cells in soft agar...PTP gamma) in human breast cancer cell line MCF-7...Enzymology, Oncology and Breast Cancer. This article was prepared by Women's Health Weekly editors from staff...
- HCCR-2 related to breast cancer development and p53 tumor suppressor regulation.
- Magazine article from: Women's Health Weekly May 6, 2004 700+ words
...Transgenic mouse model for breast cancer: induction of breast cancer in novel oncogene HCCR...Biotechnology, Oncogenesis and Breast Cancer. This article was prepared by Women's Health Weekly editors from staff and other...
- Older breast cancer patients in Canada benefit from early detection.
- Magazine article from: Women's Health Weekly June 24, 2004 700+ words
...year survival of 2192 breast cancer women diagnosed between...Survival of women with breast cancer in Ottawa, Canada...amp; Mortality, and Breast Cancer. This article was prepared by Women's Health Weekly editors from staff...
- Gene patterns in the ERBB2/TOP2A region of breast cancer influence outcomes.
- Magazine article from: Women's Health Weekly June 17, 2004 700+ words
...ERBB2/TOP2A region of breast cancer influence outcomes...ERBB2/TOP2A region in breast cancer. Gene Chromosome Cancer...Oncogenesis, Oncology and Breast Cancer. This article was prepared by Women's Health Weekly editors from staff...
- Cystatin M is a novel candidate tumor suppressor gene for breast cancer.
- Magazine article from: Women's Health Weekly December 30, 2004 700+ words
...suppressor gene for breast cancer," Zhang concluded...suppressor gene for breast cancer. Cancer Res, 2004...Suppressor Gene and Breast Cancer. This article was prepared by Women's Health Weekly editors from staff...
Source: HighBeam Research, Patients switched from tamoxifen to exemestane more likely to stay...